Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CSL ( (AU:CSL) ) has provided an announcement.
CSL Limited has disclosed a change in the interests of non-executive director Constantine Saroukos, who has indirectly acquired 512 rights under the CSL Limited Non-Executive Director Rights Plan. These rights, held via Solium Nominees (Australia) Pty Ltd as custodian, entitle him to receive one ordinary share per right, with a total consideration of $78,076.19 based on a volume-weighted average price.
The transaction reflects Saroukos contributing a portion of his board fees to acquire equity in CSL, reinforcing alignment between director compensation and shareholder interests. While the change is relatively modest in scale, it underscores the company’s ongoing use of equity-based remuneration structures to incentivize governance stability and long-term commitment from its board members.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$170.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited is a global biotechnology company focused on developing and supplying biopharmaceutical products, including vaccines, plasma-derived therapies, and specialty medicines. The company serves healthcare markets worldwide, targeting serious and chronic medical conditions through innovative therapies and related services.
YTD Price Performance: -10.69%
Average Trading Volume: 1,067,613
Technical Sentiment Signal: Sell
Current Market Cap: A$74.1B
For detailed information about CSL stock, go to TipRanks’ Stock Analysis page.